Published in Molecules: Coumarin Derivatives as Anti cancer Agents

🧬 𝗺𝗥𝗡𝗔 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗶𝘀 𝗺𝗼𝘃𝗶𝗻𝗴 𝗯𝗲𝘆𝗼𝗻𝗱 𝘃𝗮𝗰𝗰𝗶𝗻𝗲𝘀 - 𝗶𝘁’𝘀 𝗱𝗿𝗶𝘃𝗶𝗻𝗴 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆. In the latest issue of 𝘐𝘯𝘵𝘦𝘳𝘯𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘉𝘪𝘰𝘱𝘩𝘢𝘳𝘮𝘢𝘤𝘦𝘶𝘵𝘪𝘤𝘢𝘭 𝘐𝘯𝘥𝘶𝘴𝘵𝘳𝘺, Xavier Warnet, PhD, Project Manager at Tebubio’s CRO Services (https://lnkd.in/eV_CnirF), explores how 𝗟𝗶𝗽𝗶𝗱 𝗡𝗮𝗻𝗼𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀 (𝗟𝗡𝗣𝘀) are transforming RNA delivery in cancer research. 🔬 Discover how Tebubio supports scientists shaping the next generation of RNA-based therapeutics. 👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗵𝗲𝗿𝗲: https://lnkd.in/eZ9QFQ2W #mRNA #OncologyResearch #LNP #DrugDiscovery #CRO #Tebubio [WeAreTebubio]

We’re excited to share that QUANTRO Therapeutics has extended its strategic collaboration with Boehringer Ingelheim for another two years. This builds on the successful completion of a major high-throughput screening (HTS) campaign and identification of attractive hits for further development. Together, we aim to develop first-in-class drug candidates targeting transcription factors to address high unmet needs in cancer patients. Under the agreement, QUANTRO is eligible for milestone payments of up to €500M. Meet us at BIO-Europe 2025 in Vienna (Nov 3–5) to learn more about how our time-resolved transcriptomics platform is redefining what’s possible in cancer drug discovery. See the full press release here: https://lnkd.in/dzV2XNjE

The impact of ADCs on drug discovery Antibody-drug conjugates (ADCs) offer a targeted approach to cancer treatment, combining the specificity of antibodies with the potency of cytotoxic drugs, and have shown promise in improving patient outcomes. This eBook, sponsored by Abzena, explores the latest developments in the ADC field and the opportunities presented by next generation bioconjugates.   Download this exclusive eBook to learn more about:  - How targeted therapies can reduce cancer side effects - The challenges in solid tumour targeting with bispecific ADCs - The future potential for ADCs - The rise of the bioconjugates Access this eBook for FREE now https://lnkd.in/ed9iprP2 Follow DDW; Business insights for the global scientific community #DrugDiscovery #CancerResearch #DrugDevelopment

Driving innovation in small-molecule oncology drugs! Ever wonder how cancer treatment has advanced from a “no treatment” diagnosis to today’s targeted therapies? The answer lies in the incredible evolution of small-molecule drugs. This article by C&EN, featuring Lonza’s insights, takes us on a journey through the past, present, and future of small-molecule oncology. It’s a fascinating look at how scientific breakthroughs have enabled drugs to move beyond traditional models. Read about how specialized partners and advanced technologies are helping to accelerate innovation and shape a future where cancer diagnoses are a solvable challenge. Read the full article: https://ow.ly/3qSi30sQh8g #Pharma #Innovation #DrugDevelopment #Lonza

LifeArc Ventures Investment Principal Chris Baker is attending the 2025 Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts this week. Hosted by the American Association for Cancer Research, the National Cancer Institute, and the EORTC - European Organisation for Research and Treatment of Cancer, the conference brings together academics, scientists, regulators, investors, and biotech and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials. https://lnkd.in/guz-xUhE #LifeArc

Exelixis & CABOMETYX: Transformative Cancer Treatment 🧬 Exelixis (Nasdaq) has announced that CABOMETYX® (cabozantinib) significantly reduces tumor progression and death risk by 81% in advanced liver and kidney cancers, based on recent phase 3 trial results. This “game-changer” stands out in oncology for providing targeted, personalized treatment options. The drug’s success underscores the importance of precision biotech innovation in rewriting survival outcomes, with potential to extend lives and improve quality of life for thousands of patients worldwide. Exelixis’ commitment to rapid, high-impact clinical trials accelerates the pace of breakthroughs in cancer therapy. #HealthcareInnovation #CancerResearch #Biotech #ClinicalTrials #Oncology #MedicalBreakthroughs #PrecisionMedicine #LifeScience #PharmaInnovation #ScienceForSociety 🔗 More about their research: https://www.exelixis.com/

Antibody-drug conjugates (ADCs) offer a targeted approach to cancer treatment, combining the specificity of antibodies with the potency of cytotoxic drugs, and have shown promise in improving patient outcomes. Our recent sponsored e-book in Drug Discovery World, explores the latest developments in the ADC field and the opportunities presented by next generation bioconjugates. Download this exclusive eBook to learn more about: - How targeted therapies can reduce cancer side effects - The challenges in solid tumour targeting with bispecific ADCs - The future potential for ADCs - The rise of the bioconjugates Access this eBook for FREE now: https://lnkd.in/ed9iprP2 #ADCs #Bioconjugates #DrugDiscovery #CDMO #CRO

✨ In this exclusive ONCOLife interview, we spoke with Dr. Eleni Lagkadinou, MD PhD, Vice President and Head of Oncology Early Development at AbbVie, about two of the company’s most exciting investigational therapies:" ✅ ABBV-969 – a dual-targeted antibody-drug conjugate (#ADCs) for advanced #prostatecancer ✅ ABBV-514 – a novel #immunotherapy designed to deplete tumor-infiltrating regulatory T cells (#Tregs) We discussed early clinical insights from AbbVie’s expanding #oncology pipeline and the company’s commitment to tackling hard-to-treat cancers through #precisionmedicine and translational science. 🧬 From ADC engineering to IO resistance, Dr. Lagkadinou shared the scientific vision driving #AbbVie’s next wave of #cancer innovation. ➡️ Read the full interview: https://lnkd.in/dbJnZ-Hw

Roche bets $80M upfront on Hansoh Bio’s cancer ADC — a bold move that could be worth up to $1.45B in milestones. This deal isn’t just about one therapy — it’s a snapshot of where oncology innovation is heading: - Big Pharma doubling down on antibody-drug conjugates (ADCs) - Chinese biotechs stepping onto the global licensing stage - Partnerships redefining risk, reward & reach in life sciences 💬 What does this mean for the future of biotech deal-making and R&D strategy? At Luminary Group Group, we help leaders read between the lines of these moves — and act on what’s next. 👉 Follow Luminary Group for sharp takes on pharma strategy, biotech trends & deal intelligence that matter. #BiotechDeals #OncologyInnovation #PharmaStrategy #LifeSciences #ADCTherapies #LuminaryGroup https://lnkd.in/e7MrMpxb

💡 Innovation in action: University of Colorado Anschutz researcher–turned–innovator Dan LaBarbera launched Onconaut to fight metastatic #colorectalcancer and other hard-to-treat cancers. Built on discoveries around the CHD1L oncogene—a key driver of tumor progression and drug resistance—Onconaut is developing best-in-class inhibitors that, in preclinical models, amplify the effectiveness of chemo and targeted therapies up to 1,000-fold. 👉 Learn more: https://lnkd.in/eTxVw4fd Colorectal cancer is the 2nd leading cause of cancer deaths globally, with a 5-year survival rate of just 13% in advanced cases. Onconaut’s work could change that trajectory. We’re proud to celebrate Dr. LaBarbera and his team for securing a $2.5M NIH–NCI Fast-Track STTR grant, and to support their journey with partners like Fitzsimons Innovation Community and InnoSphere Ventures. #CUInnovations #CancerResearch #HealthcareInnovation University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences